Literature DB >> 2192771

Failure of selenium-ace to improve osteoarthritis.

J Hill1, H A Bird.   

Abstract

Selenium-ACE, a formulation containing the trace element selenium with three vitamins, is widely promoted for the treatment of arthritis. A controlled double-blind trial of Selenium-ACE in osteoarthritis failed to demonstrate any significant efficacy for the compound over placebo at 3 or 6 months though there was a non-significant trend to improvement in some clinical parameters in both groups. Side-effects were more frequently seen in the placebo group.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2192771     DOI: 10.1093/rheumatology/29.3.211

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN: 0263-7103


  6 in total

1.  Associations between dietary antioxidants intake and radiographic knee osteoarthritis.

Authors:  Hui Li; Chao Zeng; Jie Wei; Tuo Yang; Shu-Guang Gao; Yu-Sheng Li; Guang-Hua Lei
Journal:  Clin Rheumatol       Date:  2016-01-19       Impact factor: 2.980

2.  Effects of Glucosamine and Chondroitin Sulfate on Cartilage Metabolism in OA: Outlook on Other Nutrient Partners Especially Omega-3 Fatty Acids.

Authors:  Jörg Jerosch
Journal:  Int J Rheumatol       Date:  2011-08-02

3.  Relationship between Total Fruit and Vegetable Intake and Self-Reported Knee Pain in Older Adults.

Authors:  H S Han; C B Chang; D-C Lee; J-Y Lee
Journal:  J Nutr Health Aging       Date:  2017       Impact factor: 5.285

Review 4.  Osteoarthritis and nutrition. From nutraceuticals to functional foods: a systematic review of the scientific evidence.

Authors:  Laurent G Ameye; Winnie S S Chee
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

5.  Phytalgic, a food supplement, vs placebo in patients with osteoarthritis of the knee or hip: a randomised double-blind placebo-controlled clinical trial.

Authors:  Alain Jacquet; Pierre-Olivier Girodet; Antoine Pariente; Karelle Forest; Laurent Mallet; Nicholas Moore
Journal:  Arthritis Res Ther       Date:  2009-12-16       Impact factor: 5.156

6.  Clinical trials, progression-speed differentiating features and swiftness rule of the innovative targets of first-in-class drugs.

Authors:  Ying Hong Li; Xiao Xu Li; Jia Jun Hong; Yun Xia Wang; Jian Bo Fu; Hong Yang; Chun Yan Yu; Feng Cheng Li; Jie Hu; Wei Wei Xue; Yu Yang Jiang; Yu Zong Chen; Feng Zhu
Journal:  Brief Bioinform       Date:  2020-03-23       Impact factor: 11.622

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.